Nanocarrier-Based Delivery of Minoxidil: Current Perspectives and Future Directions in Alopecia Therapy

This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.

This study discusses the limitations of current FDA-approved treatments for androgenic alopecia, noting significant sexual side effects with oral finasteride and formulation challenges with topical minoxidil, and highlights the potential of nanocarriers to improve drug delivery to hair follicles.

This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.

This research observed that nanocarrier formulations of minoxidil improve follicular targeting and hair-growth outcomes in experimental settings, but their clinical efficacy and safety for treating androgenetic alopecia in patients remain unverified, necessitating further randomized clinical trials.